AzTrials
AzTrials

Spinal Cord DiseaseSPINE2NCT02885870

Combination of Multiparametric MRI and Electrophysiology for the Development of New Biomarkers in Spinal Cord Diseases

A study testing Combination of multiparametric MRI and electrophysiology in people with Spinal Cord Disease, run by Institut de Recherche sur la Moelle épinière et l'Encéphale at 1 site in France.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

The spinal cord is a common site for the development of several neurodegenerative neurological disorders (spinal muscular atrophy or SMA, amyotrophic lateral sclerosis or ALS, X-linked spinal bulbar muscular atrophy or SBMA). Read more about this study

Who is it for?
Ages 18 years and olderHealthy volunteers can take part
Conditions the study is for
Spinal Cord Disease
What is being tested?
Combination of multiparametric MRI and electrophysiology
Type of treatment
Surgery or procedure
Could I receive a placebo?
No, everyone receives an active treatment
How many people
25 participants
Where
1 siteFrance
Study dates
18 Apr 2016to 27 Feb 2019
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • Healthy volunteers accepted
  • Adult, Older adult

Who may be able to join

  • Spinal muscular atrophy patients :
  • Slowly progressive weakness related to pure lower motor neuron involvement X-linked spinobulbar muscular atrophy patients
  • Diagnosis confirmed by genetic testing (expansion of CAG trinucleotide repeats in the androgen receptor gene) Amyotrophic lateral sclerosis patients
  • ALS definite or probable according to El Escorial criteria - No bulbar or breathing impairment preventing decubitus
  • Healthy volunteers
  • Subjects without any neurologic or spine affection - Subjects matched for sex and age

Who cannot join

  • Subjects not able to understand the investigator
  • Subjects who are not affiliated to the national health insurance fund
  • Contraindications to resonance imaging
  • Contraindication to transcranial magnetic stimulation

Trial locations and contacts

1 site in 1 country.

France1 site
  • La Pitie Salpetrieres

    Paris, 75013

Other trials in France

About this study

The spinal cord is a common site for the development of several neurodegenerative neurological disorders (spinal muscular atrophy or SMA, amyotrophic lateral sclerosis or ALS, X-linked spinal bulbar muscular atrophy or SBMA). In different proportions, these diseases involve axonal loss in large funiculi of the spinal white matter, their demyelination, and loss of ventral horn motor neurons or motoneurones of the spinal gray matter. The lack of specific biomarkers of these macro and microscopic spinal damages, makes it difficult the differential diagnosis and monitoring of these diseases.

Techniques to explore non-invasively the human central nervous system, such as magnetic resonance imaging (MRI) and electrophysiology, are potential tools to extract specific biomarkers of spinal damages. However, imaging techniques are still poorly developed at spinal level for technical (specific antennas), anatomical (size of the spinal cord, vertebrae) and physiological reasons (cardio-respiratory movements). However, recent advances in the field of spinal cord imaging allowed to extract quantitative data on neuron loss, axonal degeneration and demyelination in different spinal pathologies whether degenerative (ALS or SMA) or traumatic (SCI). Correlations were found with clinical data, and in ALS patients, the changes in MRI metrics over time paralleled the functional deterioration. The electrophysiological techniques are used since a long time, leading to a good knowledge of the neurophysiology of human spinal cord. In addition, electrophysiology indirectly provides data at a microscopic scale, providing information on the excitability of spinal neural networks and giving an estimate of the amount of functional neurons.

Read more

By combining these techniques for the investigation of human spinal cord in vivo, the goal is to extract new biomarkers using as study models, diseases of the spinal cord affecting differentially the white and the gray matter (SMA, SBMA and ALS).

At first, new methods of diffusion MRI and modelling will be performed in healthy subjects to assess the axonal density and diameter of the fibers in the white matter. The anatomical imaging T2 will measure the geometrical parameters of the spinal cord such as its surface and/or volume at a given vertebral level. Thanks to imaging, we will construct via methods of segmentation and image processing, an atlas of the spinal cord that will allow to locate spatially spinal atrophy in patients. After this phase of validation, A study of patients will be conducted using these new MRI techniques, in addition to those already developed in the laboratory. The contribution of electrophysiology will be to assess more accurately the microscopic damage. Quantitative data from imaging and electrophysiology will be correlated with clinical data in order to extract the most relevant biomarkers.

This project has thus a methodological interest by proposing the development of new methods to assess the human spinal cord, at both macro and microscopic levels. These methods are based on the development of the techniques developed at spinal level and which are already applicable to human pathologies. The original combination of imaging and electrophysiology will also enable us to further analyze the human spinal cord, both anatomically and functionally. This project has an important clinical value for the extraction of biomarkers in diseases where there is an unmet need for diagnosis, monitoring, prognosis and evaluation of new therapies.

Being tested
Combination of multiparametric MRI and electrophysiology
Keywords
biomarker, spinal cord disease, resonance imaging, electrophysiology
Medical subject headings
Spinal Cord Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Combination of multiparametric MRI and electrophysiologyProcedure or surgery

    MRI and electrophysiology will be combined in order to assess the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration will be developed and validated in pathologies that affect differentially white and grey matter: spinal muscular atrophy, X-linked spinal bulbar muscular atrophy and Amyotrophic lateral sclerosis

Study groups in NCT02885870
Study groupRoleWhat they receive
PatientExperimentalPatient with : * Spinal muscular atrophy (n=25) * X-linked spinobulbar muscular atrophy (n=25) * Amyotrophic lateral sclerosis (n=25)
Receives: Procedure: Combination of multiparametric MRI and electrophysiology
Healthy subjectExperimentalSubject without any neurologic or spine affection Subject matched for sex and age with patient arm
Receives: Procedure: Combination of multiparametric MRI and electrophysiology

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Change in MRI from baseline to follow-up visit

    Assessment of the human spinal cord, at both macro and microscopic levels. Specific biomarkers of white and grey matter degeneration.

    Measured: Baseline, 6 months (amyotrophic lateral sclerosis patients) or 18 months (Spinal muscular atrophy and X-linked spinobulbar muscular atrophy patients)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted1 Sep 2016 (estimated)
  2. Study start18 Apr 2016
  3. Primary completion27 Feb 2019
  4. Study completion27 Feb 2019

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Non-randomised
Intervention model
Parallel groups
Masking
None (open label)
Enrolment
25 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02885870
Sponsor's protocol ID
2015-A01164-45
Acronym
SPINE2
Status last verified
Jan 2021
First submitted
22 Aug 2016
Last updated
12 Jan 2021
Results posted
No
Data monitoring committee
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

A study testing Combination of multiparametric MRI and electrophysiology in people with Spinal Cord Disease, run by Institut de Recherche sur la Moelle épinière et l'Encéphale at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 6 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 12 Jan 2021. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Change in MRI from baseline to follow-up visit (time frame: Baseline, 6 months (amyotrophic lateral sclerosis patients) or 18 months (Spinal muscular atrophy and X-linked spinobulbar muscular atrophy patients)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jan 2021.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in